When Is Growth Hormone Used for Short Stature in Children?

Medically reviewed by Dr. Fowad Shahzad · Evidence current through 20 August 2026 · Next review 20 August 2027, or sooner after a material guideline, label or DRAP change.

When a child is much shorter than classmates, parents understandably ask whether growth hormone can help. The honest answer is not a simple yes or no. Short stature is a finding, not a diagnosis, and most short children do not have growth hormone deficiency. Some are healthy and following their family pattern; some are late bloomers; others have a nutritional, thyroid, intestinal, kidney, genetic, skeletal or other medical problem that needs a different treatment.

Recombinant human growth hormone—called somatropin—can be highly valuable for a child with a well-established indication and open growth plates. It is not a guaranteed route to a chosen adult height. Diagnosis must come before injections, expectations must be realistic, and treatment requires regular specialist monitoring.

The essential points for parents

• A child’s growth velocity over time is often more informative than one height measurement.
• A left hand and wrist bone-age X-ray estimates skeletal maturity and remaining growth potential. It does not diagnose growth hormone deficiency or predict an exact adult height.
• A random growth hormone blood level is usually not useful because the hormone is released in pulses.
• Growth hormone treatment is appropriate only for defined conditions after a structured assessment. It is not recommended routinely for every healthy short child.
• Traditional daily somatropin is injected subcutaneously on six or seven days per week. Once-weekly long-acting growth-hormone products are approved for specific paediatric GHD populations in some jurisdictions, but they are not interchangeable and this article does not establish Pakistan registration or availability.
• Response varies with the diagnosis, age, puberty, growth-plate maturity, genetics, dose, adherence and other illnesses.
• Once the growth plates have fused, growth hormone cannot lengthen the long bones or make a child taller.
• Severe headache or visual symptoms, a new limp or hip/knee pain, and new breathing pauses during sleep require prompt medical assessment.

Before treatment: establish why growth is slow

This page focuses on growth-hormone treatment. For the full differential diagnosis, growth-chart explanation and initial work-up, start with Short height in children—causes and assessment.

Growth hormone deficiency is uncommon. A treatment decision begins with accurate serial height and weight measurements, growth velocity, family height, birth history and pubertal stage—not with an isolated height percentile or a random GH result. Prompt paediatric review is especially important when poor growth occurs with severe headache or visual change, recurrent hypoglycaemia in an infant, neurological symptoms, or concern for more than one pituitary-hormone deficiency.

What bone age contributes

A left hand/wrist radiograph estimates skeletal maturity and helps judge whether growth plates remain open. Delayed bone age can occur in constitutional delay, growth hormone deficiency, hypothyroidism, undernutrition and chronic illness; advanced bone age has other causes. Bone age therefore neither diagnoses growth hormone deficiency nor predicts an exact adult height. Historical reference standards and adult-height prediction methods also have population and observer limitations. There is no universal bone-age number that by itself determines treatment eligibility or stopping; diagnosis, growth velocity, pubertal stage, epiphyseal status and the exact product label must be considered together.

Somatropin cannot lengthen long bones after epiphyseal fusion. Current US somatropin labels contraindicate paediatric growth promotion when epiphyses are closed. Pediatric Endocrine Society guidance also recommends that paediatric GH doses not continue once growth velocity is below 2–2.5 cm/year; any earlier discontinuation decision should be individualized.

What testing can—and cannot—show

A random GH level is not diagnostic because secretion is pulsatile. IGF-1 can support the evaluation but must be interpreted for age and pubertal stage and can be lowered by undernutrition or chronic illness. Selected children need standardized stimulation testing; PES and the Growth Hormone Research Society caution that a stimulation result should not be the sole diagnostic criterion.

In a girl with otherwise unexplained short stature, appropriate chromosome testing to exclude Turner syndrome may be indicated even when classic physical features are absent.

Pituitary/hypothalamic MRI is not a screening test for every short child. GHRS recommends MRI in all children diagnosed with growth hormone deficiency to assess structural disease and the risk of other pituitary deficits; obtain it earlier when neurological symptoms, congenital midline signs or multiple pituitary-hormone deficiencies raise concern.

Who may be considered for somatropin?

Established growth hormone deficiency

In a child with confirmed growth hormone deficiency and open growth plates, recombinant growth hormone replaces a hormone the body is not producing adequately. This is the clearest indication: treatment usually accelerates growth and can improve adult-height outcome, although the individual result still varies.

Selected non-GH-deficient conditions

Depending on the country, the exact product label and the child’s diagnosis, somatropin may be used in selected children with conditions such as Turner syndrome, persistent short stature after being born small for gestational age, SHOX deficiency or Prader–Willi syndrome. Not every product carries every indication, and each condition has its own safety checks and goals.

Idiopathic short stature

Idiopathic short stature means that a child is very short after a structured evaluation has not found another cause. It is a diagnosis of exclusion, not another name for growth hormone deficiency.

The Pediatric Endocrine Society recommends shared, case-by-case decision-making for children who meet the relevant regulatory criteria and advises against routine growth hormone use in every child below the height threshold. Some children respond meaningfully; others respond little. Not starting treatment is also a reasonable option.

Pakistan regulatory note

Regulatory approval and product indications vary by country and brand. During preparation of this article on 20 August 2026, the official DRAP portal provided a public Registered Drugs Index, but that index described itself as provisional and warned that it may contain omissions or errors. A reliable, product-specific public record establishing the current approved paediatric indications for human somatropin in Pakistan was not obtained.

Accordingly, this article does not claim that any named somatropin brand or indication is currently DRAP-approved or available. Before prescribing or dispensing, the treating clinician and pharmacist should verify the exact product, registration number, approved indication, local prescribing information, batch, expiry and cold-chain requirements directly through current official records.

How are growth-hormone medicines given?

Traditional daily somatropin products are injected subcutaneously; the current US GENOTROPIN and HUMATROPE labels divide the calculated weekly paediatric dose into equal injections on six or seven days per week. Once-weekly long-acting growth-hormone products are approved for specific paediatric GHD populations in some jurisdictions. Daily and weekly products differ in molecule, age and indication, device, dose, missed-dose rules, monitoring and storage; they are not automatically interchangeable, and this article does not establish that any weekly product is registered or available in Pakistan.

Families should receive hands-on training that covers:

• preparing and checking the correct pen or cartridge;
• confirming the prescribed dose on every injection;
• rotating the abdomen, thigh, buttock or upper-arm sites to reduce local tissue injury;
• never sharing a pen, cartridge or needle;
• safe needle disposal;
• the exact refrigerator, light-protection and in-use storage rules for that product;
• what to do during travel or a power outage; and
• what to do after a missed or uncertain dose.

Do not calculate a child’s dose from an internet article, another child’s prescription or a bodybuilding source. Do not double a dose after a missed injection unless the prescribing team specifically instructs it.

What benefits can parents realistically expect?

In confirmed growth hormone deficiency

The expected first benefit is a faster growth velocity. Many children show the largest catch-up response in the first treatment year, with a smaller rate thereafter. The treatment goal is an improved, individualized growth trajectory—not a promised number of centimetres or a guaranteed percentile.

In idiopathic short stature

Evidence shows a modest average adult-height benefit with very wide variation. A systematic review of three small randomized trials involving 115 children found a mean adult-height difference of 0.65 standard-deviation score—about 4 cm (95% confidence interval 0.40 to 0.91)—after a mean 5.4 years of treatment. That group average cannot predict one child’s result, and the overall evidence quality was low because the studies were small and heterogeneous and had important follow-up limitations.

Why outcomes differ

Response is influenced by:

• the underlying diagnosis and severity;
• age and height when treatment starts;
• bone age and pubertal stage;
• parental height and genetic factors;
• dose and sensitivity to GH;
• nutrition, thyroid status and chronic illness;
• adherence and correct injection technique; and
• how much time remains before growth-plate fusion.

A predicted adult height is an estimate, not a contract. Even with good adherence, a child may not reach the family’s hoped-for height.

What should be agreed before starting?

A responsible pre-treatment discussion should cover:

1. the exact diagnosis and why somatropin is being considered;
2. whether the product is approved for that indication in the relevant jurisdiction;
3. growth plates, bone age and remaining growth window;
4. the realistic best estimate of benefit and its uncertainty;
5. injection schedule and device burden, the child’s preferences and family capacity;
6. expected duration and financial cost;
7. baseline safety review and monitoring plan;
8. authentic supply and cold-chain continuity;
9. what counts as an adequate first-year response; and
10. when the team would reduce, interrupt or stop treatment.

The child should be included in the decision at an age-appropriate level. Height-related teasing deserves support, but treatment should not teach a child that being short is a personal failure.

Monitoring during treatment

The paediatric endocrine team should schedule regular follow-up rather than simply renewing injections. At every follow-up, Pediatric Endocrine Society guidance calls for pertinent history and physical examination for intracranial hypertension, slipped capital femoral epiphysis and scoliosis progression, with further testing when indicated. Monitoring is individualized but commonly includes:

• carefully measured height, weight and growth velocity;
• pubertal development and remaining growth potential;
• dose, injection technique, missed doses and injection sites;
• IGF-1 interpreted against age- and puberty-specific laboratory ranges;
• thyroid function, because hypothyroidism may appear or worsen;
• glucose or HbA1c when diabetes risk is present, and periodic glucose monitoring according to the product label and clinical risk;
• baseline fundoscopic examination and periodic review for papilloedema according to the exact product label, with urgent reassessment for severe headache, vomiting or visual symptoms;
• hip or knee pain, limp and examination for slipped capital femoral epiphysis;
• scoliosis or other skeletal problems during rapid growth;
• sleep-disordered breathing and respiratory infection, especially in Prader–Willi syndrome;
• adrenal function when a pituitary disorder or steroid replacement makes this relevant;
• tumour follow-up in coordination with oncology when there is a cancer or cranial-radiation history; and
• bone age when the result will change a decision—not automatically at every visit.

If growth is below expectation, the answer is not automatically a higher dose. The clinician should review adherence and technique, nutrition, thyroid status, coeliac or other chronic disease, puberty, advanced bone age, the original diagnosis and possible GH resistance. For idiopathic short stature, the Pediatric Endocrine Society advises assessing height benefit and psychosocial impact at about 12 months after treatment and dose optimization; stopping should be considered when benefit is inadequate.

Important adverse effects and warning symptoms

Most children do not experience every problem listed below, but families need anticipatory guidance.

Severe headache, vomiting or visual change

Somatropin can rarely be associated with intracranial hypertension and papilloedema, usually within the first eight weeks after treatment begins. A severe or persistent headache, vomiting, blurred or double vision, or visual loss needs urgent assessment and immediate contact with the prescriber.

New limp or hip/knee pain

Slipped capital femoral epiphysis (SCFE) can occur in children with endocrine disorders or during rapid growth. A new limp or hip, groin or knee pain requires prompt medical review; knee pain can be referred from the hip.

Breathing pauses, worsening snoring or daytime sleepiness

In Prader–Willi syndrome, current US labels report fatalities after somatropin initiation in children with one or more of severe obesity, a history of upper-airway obstruction or sleep apnoea, or an unidentified respiratory infection. Evaluate for airway obstruction and sleep apnoea before starting; interrupt treatment for new or increased snoring or new sleep apnoea; maintain effective weight control; and promptly assess and treat respiratory infection.

Glucose intolerance or diabetes

Growth hormone can reduce insulin sensitivity and can unmask impaired glucose tolerance or diabetes in a susceptible child. Increased thirst, frequent urination, weight loss or unusual fatigue should be reported promptly. Current labels advise periodic glucose monitoring in treated patients, with closer attention in children with obesity, Turner syndrome, a strong family history or pre-existing dysglycaemia.

Thyroid and adrenal issues

Hypothyroidism may become apparent or worsen and can also reduce the growth response. In children with pituitary disease, growth hormone treatment can reveal central thyroid or adrenal insufficiency or alter replacement needs. These are specialist monitoring issues—not reasons for families to adjust hormone doses themselves.

Scoliosis and rapid growth

Somatropin has not been shown to increase the occurrence of scoliosis, but rapid growth can progress a pre-existing curve. Children with a known curve need monitoring.

Tumour precautions

Active malignancy is contraindicated; any pre-existing malignancy must be inactive and treatment complete, and somatropin must be stopped for recurrence. Childhood cancer survivors—especially those irradiated to the brain or head—need endocrine–oncology shared planning and surveillance; second neoplasms, particularly meningiomas, have been reported. In children without associated risk factors, available data have not shown increased new malignancy versus peers, but long-term post-treatment risks remain under study.

Other problems to report

Injection-site injury or loss of fat tissue, swelling, joint pain, allergic reaction and persistent severe abdominal pain also warrant medical advice. Severe allergy or breathing difficulty is an emergency.

When should growth hormone not be used for height?

Contraindications are product-specific, and the treating specialist must check the exact current local label. Current US GENOTROPIN and HUMATROPE labels include:

• closed growth plates for paediatric height promotion;
• active malignancy;
• acute critical illness due to complications following open-heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure;
• serious hypersensitivity to the product or an ingredient;
• active proliferative or severe non-proliferative diabetic retinopathy; and
• Prader–Willi syndrome with severe obesity, a history of upper-airway obstruction or sleep apnoea, or severe respiratory impairment.

This is not an exhaustive Pakistan prescribing list. Additional contraindications and precautions vary by product and child, which is why a prescription cannot be safely based on a height percentile alone.

Myths and facts

Myth	Evidence-based fact
Every short child lacks growth hormone.	Most short children do not have growth hormone deficiency. Family height and delayed puberty are common explanations.
A low random GH level proves deficiency.	GH is released in pulses; a random value is usually not diagnostic.
Delayed bone age means the child needs injections.	Delayed bone age has several causes and may simply reflect late puberty. It is one clue, not an indication by itself.
Bone age predicts the final height exactly.	Adult-height predictions have uncertainty and may overestimate in some situations.
GH can make any child as tall as the parents choose.	Response is variable and limited by diagnosis, genetics, age, puberty and growth-plate maturity.
GH works after the growth plates close.	It cannot lengthen long bones after epiphyseal fusion.
More GH always produces more useful height.	Higher exposure can raise IGF-1 and risk without guaranteeing a better adult outcome. Dosing must be individualized.
Vitamins, protein powders or stretching replace a medical work-up.	Nutrition matters when deficient, but supplements or exercises do not treat GHD or override fused growth plates.
If the first months are disappointing, the dose should simply be doubled.	Poor response requires a review of adherence, technique, diagnosis, thyroid, nutrition, chronic disease, puberty and bone age.
All somatropin brands and devices are interchangeable.	Formulations, devices, storage, indications and dosing instructions differ. Substitution requires the prescriber and pharmacist.

Dr. Fowad’s evidence-based perspective

The safest sequence is growth chart first, diagnosis second, injection last. A left hand/wrist bone-age film can add useful information about skeletal maturity, but it should never be used alone to sell a height treatment.

For a child with confirmed growth hormone deficiency and open growth plates, somatropin can be an important replacement therapy. For idiopathic short stature, the decision is more preference-sensitive: the average benefit is modest, the response is unpredictable, treatment lasts years, and the injection and financial burden belong in the discussion. Not treating is a legitimate choice.

Before starting, families deserve a written goal, a monitoring schedule and a predefined review point. If a child is not responding despite correct treatment, the diagnosis and the value of continuing should be reconsidered. No ethical clinician should promise a specific number of centimetres or a chosen adult height.

Because this is specialist paediatric treatment, diagnosis and prescribing should be led by a paediatric endocrinologist or dedicated paediatric growth service. DrFowad.com provides education only; this page does not state that Dr. Fowad provides paediatric endocrinology or prescribes growth hormone to children.

Frequently asked questions

1. Can one blood test diagnose growth hormone deficiency?

No. A random GH level is unreliable because secretion is pulsatile. Diagnosis combines serial growth data, examination, IGF-1 and other targeted tests; selected children need standardized stimulation testing interpreted by a paediatric endocrinologist.

2. Can bone age prove my child needs growth hormone or predict exact adult height?

No. Bone age is one contextual estimate of skeletal maturity. It neither diagnoses growth hormone deficiency nor predicts an exact adult height; diagnosis, growth velocity, puberty and epiphyseal status must be interpreted together.

3. Can somatropin work after the growth plates close?

Not for height. Once the epiphyses are fused, the long bones cannot be lengthened by growth hormone. Adults with proven GHD may receive GH for different metabolic indications, but that is not height treatment.

4. Is somatropin injected every day?

Traditional paediatric somatropin is usually divided into injections on six or seven days per week. The exact schedule is product- and diagnosis-specific. Weekly long-acting products exist in some countries but are not automatically interchangeable or available in Pakistan.

5. How long does treatment continue?

Often for years, while there is a valid indication, useful response and open growth plates. Follow-up should determine whether benefit justifies continuing. Height-promoting treatment stops when growth is essentially complete or when response is inadequate.

6. How many centimetres will my child gain?

No clinician can promise a number. Children with true GHD often have a strong early response, but final height varies. In older trials of idiopathic short stature, the average adult-height difference was about 4 cm, with wide individual variability.

7. Will starting earlier always give a better result?

More remaining growth time can help, but earlier is not automatically better if the diagnosis is wrong. The priority is timely, accurate evaluation—not premature injections.

8. What is idiopathic short stature?

It is marked short stature with no identified systemic, endocrine, nutritional or chromosomal cause after appropriate evaluation. It does not mean proven GHD.

9. Is growth hormone safe?

It has decades of clinical use and an established role for approved indications, but it is not risk-free. Safe use requires authentic product, specialist dosing and monitoring for neurological, hip, metabolic, thyroid, respiratory and tumour-related concerns.

10. Does growth hormone cause cancer?

Active malignancy is contraindicated; any pre-existing malignancy must be inactive and treatment complete, and somatropin must be stopped for recurrence. Childhood cancer survivors—especially those irradiated to the brain or head—need endocrine–oncology shared planning and surveillance because second neoplasms, particularly meningiomas, have been reported. In children without associated risk factors, available data have not shown increased new malignancy versus peers, but long-term post-treatment risks remain under study.

11. Can growth hormone cause diabetes?

Somatropin can reduce insulin sensitivity and may unmask glucose intolerance or diabetes in a susceptible child. Risk assessment and appropriate glucose monitoring are important, especially with obesity or other risk factors.

12. Why are headaches important during treatment?

Rare intracranial hypertension can cause headache, vomiting and visual symptoms. Severe or persistent symptoms need urgent assessment, including examination for papilloedema.

13. Why does a limp or knee pain matter?

SCFE is a hip growth-plate problem associated with endocrine disorders and rapid growth. It may present as hip, groin, thigh or knee pain and a limp. Prompt assessment helps protect the joint.

14. Does my child need an eye examination?

Current US somatropin labels call for a fundoscopic examination before treatment to exclude papilloedema and periodic review thereafter. The treating specialist should apply the exact local product label and clinical context.

15. What about snoring and sleep apnoea?

Sleep and airway symptoms are particularly important in Prader–Willi syndrome. Severe obesity, a history of upper-airway obstruction or sleep apnoea, and severe respiratory impairment are product-label concerns. New or worsening snoring, breathing pauses, obstruction, respiratory infection or breathing difficulty should be reported immediately; the prescriber may need to interrupt treatment and arrange assessment.

16. Can GH worsen scoliosis?

Somatropin has not been shown to increase the occurrence of scoliosis, but rapid growth can progress a pre-existing curve. A known or suspected curve needs monitoring.

17. What happens if an injection is missed?

Follow the product instructions and contact the treating team if uncertain. Do not double the next dose unless specifically instructed.

18. Should injections be given at bedtime?

Some regimens traditionally use evening dosing, but the correct timing depends on the prescribed product and plan. Consistency and following the treating team’s instructions are more important than internet rules.

19. What if IGF-1 becomes high?

IGF-1 should be interpreted with the laboratory’s age- and puberty-specific range. Pediatric Endocrine Society guidance advises lowering GH exposure when IGF-1 rises above the laboratory-defined normal range; families should not change the dose themselves.

20. Can the brand be changed because another one is cheaper?

Do not switch without the prescriber and pharmacist. Device technique, concentration, excipients, reconstitution, storage, local registration and approved indications may differ.

Practical Pakistan safety checklist

• Use only the exact growth-hormone medicine prescribed for the individual child after a proper diagnosis.
• Ask the prescriber/pharmacist to verify the current DRAP registration, product-specific paediatric indication and local prescribing information.
• Obtain it through a licensed, reputable pharmacy with a traceable invoice and intact packaging.
• Check brand, generic name, strength, registration details, batch, expiry and tamper evidence.
• Confirm the required cold chain before purchase, during transport and at home; do not use a product after uncertain storage without professional advice.
• Never buy GH from a gym, social-media seller, informal importer or unverified online source.
• Never share pens, cartridges or needles.
• Arrange continuity before starting; interrupted supply, device changes and unaffordable long-term treatment should be discussed honestly.
• Report suspected quality problems or adverse reactions through the treating team and current DRAP channels.

Preparing for a growth appointment

Bring:

• the child’s vaccination book, school records and previous clinic measurements;
• birth gestation, weight and length;
• both parents’ measured heights if possible;
• family history of late puberty or unusual short stature;
• laboratory reports, scan reports and the bone-age film—not only the written report;
• all medicines, inhalers, creams, injections and supplements; and
• a written list of the family’s main questions and expectations.

For current clinic contact information, see clinic locations in Lahore and Gujranwala. Contact staff only to verify whether an appropriate paediatric referral pathway is available; this page does not offer paediatric growth-hormone treatment. Urgent symptoms require paediatric or emergency assessment.

Educational disclaimer

This article is for general education and cannot diagnose growth hormone deficiency, interpret an individual bone-age image, calculate a somatropin dose or decide whether a child should start, stop or change treatment. Paediatric growth hormone therapy should be assessed and managed by a paediatric endocrinologist or dedicated paediatric growth service using the child’s full history, examination, growth record and current local product information. Severe headache with visual symptoms, breathing difficulty, a new limp or acute illness requires prompt medical care. In an emergency, attend the nearest emergency department.

Evidence and references

Sources were checked on 20 August 2026. Product labels are cited for safety signals and examples of jurisdiction-specific indications, not as proof of Pakistan approval.

1. Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Hormone Research in Paediatrics. 2016;86:361–397. DOI: 10.1159/000452150. Pediatric Endocrine Society resource and full guideline PDF. Published 25 November 2016.
2. Collett-Solberg PF, Ambler G, Backeljauw PF, et al. Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective. Hormone Research in Paediatrics. 2019;92(1):1–14. DOI: 10.1159/000502231. PubMed. Published online 12 September 2019.
3. Pediatric Endocrine Society. Child with Suspected Short Stature. Peer-reviewed referral guidance. PES clinical resource. Revised 1 May 2020.
4. Pediatric Endocrine Society/American Academy of Pediatrics. Short Stature: A Guide for Families. PES patient resource. Resource publication 17 June 2020; underlying family guide copyright 2018.
5. U.S. National Library of Medicine DailyMed/FDA labeling. GENOTROPIN (somatropin) for injection. Current label. Revised July 2026.
6. U.S. National Library of Medicine DailyMed/FDA labeling. HUMATROPE (somatropin) for injection. Current label. Updated 25 November 2025.
7. Deodati A, Cianfarani S. Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review. BMJ. 2011;342:c7157. DOI: 10.1136/bmj.c7157. Full article. Published 11 March 2011.
8. Leschek EW, Rose SR, Yanovski JA, et al. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Endocrinology & Metabolism. 2004;89(7):3140–3148. PubMed. Published July 2004.
9. Hokken-Koelega ACS, van der Steen M, Boguszewski MCS, et al. International Consensus Guideline on Small for Gestational Age: Etiology and Management From Infancy to Early Adulthood. Endocrine Reviews. 2023;44(3):539–565. Endocrine Society summary. Published 2023.
10. Krishna KB, Witchel SF. Normal and Abnormal Puberty. Endotext, NCBI Bookshelf. Chapter. Updated 9 April 2024. Used for bone-age methods and limitations.
11. European Medicines Agency. Somatropin-containing medicines—Article 107 referral. EMA safety review. European Commission decision 27 February 2012; benefits judged to outweigh risks when used within approved indications and doses.
12. Drug Regulatory Authority of Pakistan. DRAP e-Services Portal and Registered Drugs Index. Official portal and public registered-product index. Accessed 20 August 2026. The public index describes itself as provisional and disclaims completeness/accuracy; it was not sufficient to establish a current product-specific paediatric human-somatropin indication for this article.
13. Pediatric Endocrine Society. Growth Hormone Deficiency: A Guide for Families. Patient resource. Published 17 June 2020; accessed 20 August 2026.
14. U.S. Food and Drug Administration. Drug Trials Snapshots: NGENLA. FDA snapshot. Original U.S. approval 27 June 2023; accessed 20 August 2026. Cited only to illustrate a jurisdiction-specific once-weekly paediatric GHD product, not Pakistan registration or availability.